0001612630-26-000022
SEC filingThe Joint Corp. reported FY 2025 total revenues of $54.9 million, representing a year-over-year increase from $52.2 million in FY 2024. The company achieved net income of $2.9 million, a significant improvement from a net loss of $5.8 million in the prior year. This profitability was primarily driven by a $3.2 million net income from discontinued operations related to the corporate clinic divestiture strategy, while continuing operations reported a net loss of $268K. Gross profit was $43.7 million with a gross margin of 79.6%. Operating cash flow was positive at $1.8 million, supported by proceeds from clinic sales of $7.8 million. The company's strategic shift to refranchise company-owned clinics represents a major operational change with forward-looking implications for the franchise-focused business model.
The Joint Corp. reported FY 2025 total revenues of $54.9 million, representing a 5.2% increase from $52.2 million in FY 2024. The company achieved net income of $2.9 million, a significant improvement from a net loss of $5.8 million in the prior year. This profitability turnaround was primarily driven by net income from discontinued operations of $3.2 million, while continuing operations reported a net loss of $268K. Basic earnings per share improved to $0.19 from $(0.39) in FY 2024. The company's strategic shift to refranchise company-owned clinics, with all such operations now classified as discontinued, represents a major operational change. Total assets decreased to $61.0 million from $83.2 million, reflecting the divestiture of corporate clinic assets.
Revenue growth was driven by increases across multiple revenue streams. Royalty fees, the largest component, grew to $33.2 million from $32.1 million in the prior year. Franchise fees increased to $3.4 million from $3.0 million, while advertising fund revenue rose to $10.5 million from $9.2 million. Software fees grew to $6.0 million from $5.7 million, and other revenues decreased to $1.8 million from $2.2 million. The company ended FY 2025 with 885 franchised clinics in operation, up from 842 at the end of FY 2024, demonstrating continued franchise system growth. Quarterly revenue showed sequential improvement throughout the year, with Q4 2025 reaching $15.2 million compared to Q1 2025 at $13.1 million.
Gross profit improved to $43.7 million with a gross margin of 79.6%, up from 77.9% in FY 2024. This margin expansion resulted from total cost of revenues decreasing to $11.2 million from $11.5 million despite revenue growth. However, selling, general and administrative expenses increased to $44.6 million from $42.5 million, primarily due to higher selling and marketing expenses of $13.3 million compared to $11.0 million in the prior year. General and administrative expenses decreased slightly to $29.6 million from $30.1 million. The operating loss from continuing operations was $913K, an improvement from $1.9 million in FY 2024. Other income of $684K contributed to the reduced loss from continuing operations before taxes.
Operating cash flow was positive at $1.8 million, supported by net income adjustments including depreciation and amortization of $1.7 million and stock-based compensation of $1.3 million. Investing activities provided $6.3 million in cash, primarily from proceeds from sale of clinics of $7.8 million, partially offset by property and equipment purchases of $1.5 million. Financing activities used $9.8 million in cash, mainly due to common stock repurchases of $11.3 million under authorized programs. The balance sheet shows cash and cash equivalents of $23.6 million with total current assets of $52.1 million. Total liabilities decreased to $45.9 million from $62.5 million, while stockholders' equity declined to $15.1 million from $20.7 million, affected by treasury stock purchases and accumulated deficit.
The company's strategic focus remains on refranchising all company-owned clinics, with this segment now fully classified as discontinued operations. Management has formalized plans to sell the entire corporate clinic reportable segment, representing a strategic shift with major operational implications. The company faces ongoing litigation in California with multiple lawsuits alleging various claims at company-owned clinics, though no accrual has been recorded as of December 31, 2025. Cybersecurity remains a focus area with regular testing and employee training programs implemented. The company maintains a $20.0 million revolving credit facility but was in default of covenant requirements as of December 31, 2025 due to violations of fixed charge coverage ratios primarily related to stock repurchases.